<DOC>
	<DOCNO>NCT01872013</DOCNO>
	<brief_summary>This study ass safety , tolerability , plasma concentration pharmacodynamics ASP7991 multiple oral administration non-elderly subject .</brief_summary>
	<brief_title>Multiple Oral Administration ASP7991 Non-elderly Male Subjects</brief_title>
	<detailed_description>In step ( low dose , middle dose , high dose ) , subject randomly assign double blinded manner receive either ASP7991 ( n=9 ) Placebo ( n=3 ) administer repeatedly . Once daily , subject administer ASP7991 placebo orally 30 minute breakfast 150 mL water 7 day . After step sponsor evaluate safety blind manner decide escalation step .</detailed_description>
	<criteria>Healthy , judge investigator/sub investigator base result physical examination obtain study drug administration Body weight : ≥50.0 kg , &lt; 80.0 kg BMI : ≥17.6 , &lt; 26.4 Serum correct calcium concentration : ≥9.0mg/dL , &lt; 10.4 mg/dL Received investigational drug clinical postmarketing study within 120 day screen Donated 400 mL whole blood within 90 day , 200 mL whole blood within 30 day , blood component within 14 day screen Received medication ( include market drug ) within 7 day hospitalization , vitamin preparation include vitamin D supplement include calcium schedule receive medication A deviation normal criterion range 12lead ECG ( QT evaluation ) A deviation normal range clinical laboratory test Highly sensitive cardiac troponin T ( screen ) : ≥0.014 ng/mL History drug allergy Upper gastrointestinal disease ( e.g . nausea , vomit , stomachache ) within 7 day admission Concurrent previous hepatic disease ( e.g. , viral hepatitis , druginduced liver injury ) Concurrent previous endocrine disorder ( e.g. , hyperthyroidism , aberration growth hormone )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Plasma concentration</keyword>
	<keyword>Urinary concentration</keyword>
	<keyword>ASP7991</keyword>
</DOC>